Why Lupin's Near-Term US Sales Decline Could Present a Long-Term Investment Opportunity
India, Nov. 21 -- The Indian pharmaceutical sector also provides good potential for growth, driven by growing demand for chronic products, an increase in spending on health care, and higher demand worldwide for complex generics. The pricing issues and competitive pressures within the US generics market will continue to be the major issues for Indian pharmaceutical firms that have considerable international exposure.
Against this backdrop, Lupin is concentrating on developing its formulations business in India through acquisitions and developing a pipeline of complex generics and biosimilars. Against the weak sales performance of the company in the US, Nomura expects that the stock of Lupin is attractively valued at this point.
With a m...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.